Tg Therapeutics: B. Riley Securities maintains a 'Buy' Rating, The Target Price is $55

B. Riley Securities maintains 'Buy' rating on Tg Therapeutics(TGTX).

The target price is $55, compare with $53 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-09-17	B. Riley Securities	Maintains	Buy	Buy	$55	$53

[Recent Earning Results] Tg Therapeutics posted the Q2 of its 2025 financial results on 8/8/2025, reporting total revenue of USD 262.00 million in the first half of the year, up 91.33% from USD 136.94 million year over year, reporting net income of USD 33.25 million in the first half of the year, compare with USD -3.83 million in the same period last year.

[Company Profile] TG Therapeutics, Inc. were incorporated in Delaware in 1993. The company is a fully-integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.